Status:
UNKNOWN
VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management
Lead Sponsor:
Ankara University
Conditions:
Atrial Fibrillation
Cardiac Thrombus
Eligibility:
All Genders
18-85 years
Brief Summary
The investigators aimed to use pharmacogenetic information in clinical practise which may lead to rapid, efficient, and safe warfarin dosing in this observational prospective study. In this context, t...
Detailed Description
Long-term anticoagulation therapy with warfarin is recommended for patients with atrial fibrillation/flutter (AF), left atrial thrombus, deep vein thrombosis (DVT), pulmonary thromboembolism (PE), mec...
Eligibility Criteria
Inclusion
- Patients who require warfarin for at least 6 months with the indications listed below:
- Permanent Atrial Fibrillation/Flutter
- Left atrial or ventricular thrombus
- Deep Vein Thrombosis
- Pulmonary Embolism
- Heart Valve Replacement (Mechanical or Biological With AF)
- Cardiomyopathy (Ischemic or Dilated)
- Peripheral Vascular Disease
Exclusion
- History of GI bleeding or peptic ulcer disease
- Significant liver disease, active hepatitis or chronic HBV/HCV infection
- Uncontrolled hypertension
- Chronic diarrhea or malabsorption syndrome
- Viral or bacterial infection prior to enrollment
- Active or previous infective endocarditis
- Hospital stay \> 30 days as a result of septicemia, mediastinitis or pneumonia
- Cardiac cachexia
- Morbid obesity
- Expected pregnancy, pregnancy or lactation
- Psychiatric disease
- Malignancy with Life expectancy less than 1 year
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2012
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00970892
Start Date
July 1 2009
End Date
December 1 2012
Last Update
September 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ankara University Medical Faculty, Department of Cardiovascular Surgery and Pulmonary Disease
Ankara, Turkey (Türkiye), 06340